In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected During an International Surveillance Program (2017).

In this study, we tested APX001A and comparators against 1,706 contemporary clinical fungal isolates collected worldwide during 2017 from 68 medical centers in North America (37.3%), Europe (43.4%), Asia-Pacific (12.7%), and Latin America (6.6%). Among the isolates tested, 78.5% were Candida spp., 3.9% were non-Candida yeasts, including 30 Cryptococcus neoformans var. grubii (1.8%), 14.7% were Aspergillus spp., and 2.9% were other moulds. All isolates were tested by CLSI reference broth microdilution.APX001A (MIC50/90, 0.008/0.06 μg/ml) was the most active agent tested against Candida spp. isolates; corresponding anidulafungin, micafungin, and fluconazole MIC90 values were 16- to 64-fold higher. Similarly, APX001A (MIC50/90, 0.25/0.5 μg/ml) was ≥8-fold more active than anidulafungin, micafungin, and fluconazole against C. neoformans var. grubii Against Aspergillus spp., AXP001A (MEC50/90, 0.015/0.03 μg/ml) was comparable in activity to anidulafungin and micafungin. Aspergillus isolates (>98%) exhibited a wild-type phenotype for the mould active triazoles (itraconazole, posaconazole, and voriconazole). APX001A was highly active against uncommon species of Candida, non-Candida yeasts, and rare moulds, including 11 isolates of Scedosporium spp. (MEC values, 0.015-0.06 μg/ml).APX001A demonstrated potent in vitro activity against recent fungal isolates, including echinocandin- and fluconazole-resistant strains. The extended spectrum of APX001A was also notable for its pot...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research